Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Denis Glotz, Graeme Russ, Lionel Rostaing, Christophe Legendre, Gunnar Tufveson, Steve Chadban, Josep Grinyó, Nizam Mamode, Paolo Rigotti, Lionel Couzi, Matthias Büchler, Silvio Sandrini, Bradley Dain, Mary Garfield, Masayo Ogawa, Tristan Richard, William H Marks, undefined C10-002 Study Group
Am J Transplant | Published : 2019
The presence of preformed donor-specific antibodies in transplant recipients increases the risk of acute antibody-mediated rejection (AMR). Results of an open-label single-arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased-donor kidney transplants with preformed donor-specific antibodies are reported. Participants received eculizumab as follows: 1200 mg immediately before reperfusion; 900 mg on posttransplant days 1, 7, 14, 21, and 28; and 1200 mg at weeks 5, 7, and 9. All patients received thymoglobulin induction therapy and standard maintenance immunosuppression including steroids. The primary end point was treatment failure rate, ..View full abstract